Physician profile
Jessica B Sharp
NPI 1629164280
$9,733.32
in general payments reported to CMS, 2019-2025
46 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,402 · 2022: $2,020 · 2023: $2,074 · 2024: $1,529 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,256 · Education: $54.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,256.48 |
| Education | $54.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,473.67 | 2021-2025 | |
| Amgen INC. | $1,004.12 | 2021-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $880.12 | 2021-2025 | Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $724.40 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $656.88 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $442.59 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $433.98 | 2022-2025 | |
| Pfizer INC. | $378.31 | 2021-2025 | |
| Glaxosmithkline, LLC. | $375.85 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.41 | 2021-2025 | Jardiance, Synjardy |
| Antares Pharma, INC. | $263.40 | 2021-2025 | Xyosted |
| Abbott Laboratories | $245.66 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $228.56 | 2023-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $223.06 | 2021-2024 | Livalo, Seglentis |
| Biohaven Pharmaceuticals, INC. | $209.37 | 2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.